The FDA has chastised Lundbeck Seattle Biopharmaceuticals for two promotional webpages, neither of which is still online, that made allegedly inflated claims regarding the efficacy of its migraine drug. In an
Source: Endpoints News
You may also like
Deals, deals, deals; Biohaven takes on Eli Lilly; and...
German lawmakers pass cost-saving bill that drugmakers...
This common pesticide may be quietly wiping out future...
Boehringer Ingelheim’s Jascayd approved by MHRA for...
Ipsen to acquire Memo Therapeutics in deal worth more...
Macrophage Membrane-Derived Nanoparticles Shows...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.